PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 2026Cancer Biology & Therapy2 citationsOpen Access

Glutamine transporter SLC1A5 inhibits autophagy-mediated CD276 degradation to promote esophageal cancer progression

View Full Paper
CWChunyan WangHZHeng ZhangCGChaonan Guan

Key Points

  • The research aims to understand how SLC1A5 affects CD276 stability and esophageal cancer progression.
  • Investigated the role of SLC1A5 in regulating CD276 stability
  • Analyzed the impact of ROS-autophagy signaling on CD276 degradation
  • Explored potential therapeutic strategies targeting glutamine metabolism for ESCC
  • SLC1A5 was found to enhance CD276 stability
  • Inhibition of ROS-autophagy signaling was linked to increased CD276 levels
  • Suggests targeting glutamine metabolism could improve CD276 degradation and combat ESCC progression

Abstract

SLC1A5 enhances CD276 stability by suppressing ROS-autophagy signaling, promoting ESCC progression. Targeting glutamine metabolism to enhance CD276 degradation might be a novel therapeutic strategy for ESCC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6980fcfcc1c9540dea80ec2ahttps://doi.org/10.1080/15384047.2026.2621606
Ask AI
Helpful
Bookmark
Share
View Full Paper